Inscription Capital LLC Makes New Investment in Becton, Dickinson and Company (NYSE:BDX)

Inscription Capital LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,455 shares of the medical instruments supplier’s stock, valued at approximately $360,000.

Several other institutional investors also recently modified their holdings of BDX. Louisbourg Investments Inc. lifted its holdings in Becton, Dickinson and Company by 5.0% in the first quarter. Louisbourg Investments Inc. now owns 36,510 shares of the medical instruments supplier’s stock valued at $8,363,000 after buying an additional 1,745 shares during the period. QRG Capital Management Inc. lifted its stake in shares of Becton, Dickinson and Company by 9.3% in the 1st quarter. QRG Capital Management Inc. now owns 9,272 shares of the medical instruments supplier’s stock valued at $2,124,000 after purchasing an additional 789 shares during the period. Sagespring Wealth Partners LLC lifted its stake in shares of Becton, Dickinson and Company by 18.0% in the 1st quarter. Sagespring Wealth Partners LLC now owns 4,079 shares of the medical instruments supplier’s stock valued at $934,000 after purchasing an additional 621 shares during the period. Great Lakes Retirement Inc. boosted its position in shares of Becton, Dickinson and Company by 14.5% in the 1st quarter. Great Lakes Retirement Inc. now owns 4,566 shares of the medical instruments supplier’s stock worth $1,046,000 after purchasing an additional 578 shares during the last quarter. Finally, Lorne Steinberg Wealth Management Inc. grew its stake in shares of Becton, Dickinson and Company by 0.4% during the first quarter. Lorne Steinberg Wealth Management Inc. now owns 27,793 shares of the medical instruments supplier’s stock worth $6,366,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 479 shares of the firm’s stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the transaction, the executive vice president now owns 4,887 shares of the company’s stock, valued at approximately $964,107.36. This trade represents a 8.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David Shan sold 1,166 shares of the business’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president now directly owns 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on BDX shares. The Goldman Sachs Group lowered Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 target price on the stock. in a research note on Friday, May 2nd. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Morgan Stanley reduced their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 6th. Bank of America downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 target price for the company. in a research note on Thursday, May 1st. Finally, William Blair cut shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 1st. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $219.22.

Becton, Dickinson and Company Stock Down 0.8%

Shares of BDX stock opened at $168.54 on Thursday. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. The firm has a fifty day moving average of $180.85 and a 200-day moving average of $212.00. The company has a market capitalization of $48.30 billion, a price-to-earnings ratio of 32.16, a P/E/G ratio of 1.28 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the business earned $3.17 EPS. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.47%. Becton, Dickinson and Company’s payout ratio is presently 79.39%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.